Login to Your Account

Allon Hammered as Davunetide Misses in a Pivotal PSP Trial

By Staff Reports

Wednesday, December 19, 2012
Shares of Canadian firm Allon Therapeutics Inc. lost 94 percent of their value Tuesday afternoon on news that the company's pivotal study of lead candidate davunetide failed to show an effect in patients with progressive supranuclear palsy (PSP).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription